{
    "clinical_study": {
        "@rank": "164954", 
        "arm_group": {
            "arm_group_label": "75 mg of sodium risedronate", 
            "description": "75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of sodium risedronate\n      tablets (Benet 75 mg Tablets) in osteoporosis patients in daily medical practice, as well as\n      to examine \"the status of treatment compliance\" - i.e., whether sodium risedronate tablets\n      are taken properly in accordance with the prescribed once-monthly regimen"
        }, 
        "brief_title": "Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "This surveillance was designed to evaluate the safety and efficacy of sodium risedronate\n      tablets (Benet 75 mg Tablets) as well as to evaluate the status of treatment compliance in\n      osteoporosis patients in daily medical practice.\n\n      The usual dosage for adult is 75 mg of sodium risedronate administered orally with a\n      sufficient volume (approximately 180 mL) of water once monthly after waking. For at least 30\n      minutes after administration, patients should avoid lying in a supine position and should\n      avoid taking food, drink (except for water) or other oral drugs. For more details, see the\n      \"Precautions related to dosage and administration\" section of the package insert."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Osteoporosis patients\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Osteoporosis"
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089997", 
            "org_study_id": "178-001"
        }, 
        "intervention": {
            "arm_group_label": "75 mg of sodium risedronate", 
            "description": "Sodium risedronate tablets", 
            "intervention_name": "Sodium risedronate", 
            "intervention_type": "Drug", 
            "other_name": "Benet 75mg Tablets"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Risedronic acid", 
                "Etidronic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "March 14, 2014", 
        "number_of_groups": "1", 
        "official_title": "Benet 75 mg Tablets Special Drug Use Surveillance: Long-term Use (12-month Treatment Survey)", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequency of all adverse events observed during the observation period will be tabulated by symptom, type, and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of sodium risedronate, whether or not it was considered related to the treatment.", 
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "For 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089997"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tabulation of percent change in bone density for the efficacy analysis set", 
                "measure": "Change rate from baseline in bone density", 
                "safety_issue": "No", 
                "time_frame": "Pretreatment (within 3 months before the start of treatment), 6 months after, and 12 months after the start of treatment (or at the time of withdrawal)"
            }, 
            {
                "description": "Tabulation of percent change in bone metabolism markers for the efficacy analysis set", 
                "measure": "Change rate from baseline in bone metabolism markers", 
                "safety_issue": "No", 
                "time_frame": "Pretreatment (within 1 month before the start of treatment), 6 months after, and 12 months after the start of treatment (or at the time of withdrawal)"
            }, 
            {
                "description": "Tabulation of change in height for the efficacy analysis set", 
                "measure": "Time cource from baseline in height", 
                "safety_issue": "No", 
                "time_frame": "At the start of treatment and 12 months after the start of treatment (or at the time of withdrawal)"
            }, 
            {
                "description": "Tabulation of change in lumbar backache for the efficacy analysis set", 
                "measure": "Change from baseline in lumbar backache", 
                "safety_issue": "No", 
                "time_frame": "At the start of treatment, 3 months after, 6 months after, and 12 months after the start of treatment (or at the time of withdrawal)"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}